Continuous Process Verification in Pharmaceutical Manufacturing: A Lifecycle Approach to Quality Assurance

Continuous Process Verification (CPV) represents a paradigm shift in pharmaceutical manufacturing quality assurance, transitioning the industry from traditional retrospective end-product testing towards prospective, real-time process monitoring and control throughout the entire product lifecycle. This comprehensive review examines the conceptual foundations, regulatory underpinnings, and practical implementation of CPV within the three-stage lifecycle validation model as articulated in the United States Food and Drug Administration (FDA) Process Validation Guidance (2011) and aligned with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines Q8, Q9, Q10, and Q11.The review systematically addresses the identification and monitoring of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs), the development and deployment of scientifically sound control strategies, and the application of advanced statistical methodologies including Statistical Process Control (SPC), process capability analysis, and multivariate data analysis. The integration of Process Analytical Technology (PAT) as an enabling platform for real-time release testing and enhanced process understanding is discussed in depth, along with the growing role of digital transformation, artificial intelligence, and machine learning in augmenting CPV capabilities.Dosage form-specific CPV considerations are examined across oral solid dosage forms, sterile and parenteral products, biologics, and continuous manufacturing platforms. The review also addresses significant organisational, technical, and regulatory challenges that impede effective CPV implementation, drawing upon published industry case studies and regulatory inspection findings. The paper concludes with a forward-looking perspective on harmonised global regulatory standards, adaptive manufacturing, and the evolving role of CPV in supporting personalised medicine and novel therapeutic modalities. Collectively, the evidence underscores CPV as an indispensable pillar of modern pharmaceutical quality systems, enabling proactive risk management, sustained product quality, and ultimate protection of patient safety.